SQI Diagnostics (OTCMKTS:SQIDF) is a Switzerland‐based developer and manufacturer of rapid immunoassay tests and diagnostic platforms. The company focuses on point‐of‐care and laboratory‐based solutions that employ lateral flow and enzyme‐linked technologies to deliver timely results for both agricultural and human health applications. SQI Diagnostics offers fully integrated test kits, reader instruments, software interfaces, and customizable assay development services to meet a wide range of client needs.
Its product portfolio includes disposable test strips and cassettes for qualitative and quantitative detection of pathogens, as well as multiplexed assay formats capable of identifying multiple targets in a single run. In the agricultural sector, SQI Diagnostics supplies growers, crop consultants, and research institutions with on‐site assays for plant viruses, fungal diseases, and bacterial infections. In the medical segment, the company’s offerings span sexually transmitted infection panels, respiratory pathogen screens, and biomarkers for inflammatory conditions, all designed to operate in decentralized or low‐resource environments.
Headquartered in Basel, SQI Diagnostics maintains research and development facilities in Germany and leverages contract manufacturing partners across Europe to support scalable production. A global network of distributors and OEM partners extends the company’s reach into North America, Asia Pacific, and Latin America. SQI Diagnostics also collaborates with academic institutions and contract research organizations to advance assay performance and expand its pipeline of point‐of‐need diagnostics.
Founded in 2010 as a spin‐off from a leading biotechnology incubator, SQI Diagnostics has built a leadership team with deep expertise in immunochemistry, microfluidics, and regulatory strategy. The executive management group combines veterans from established diagnostic firms with entrepreneurs experienced in rapid assay commercialization. Under this leadership, the company continues to invest in next‐generation portable readers, digital result reporting, and novel assay chemistries to address emerging disease threats and evolving customer requirements.
AI Generated. May Contain Errors.